Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Your search for Warfarin returned 14 results
Quality improvement effort tied to decrease in major bleeding without increase in thrombotic events
Apixaban is a direct oral anticoagulant that relies less on kidney excretion.
Guideline addresses management of anticoagulants, antiplatelets during acute gastrointestinal bleeding and in the elective endoscopy setting
Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
Evidence currently inadequate for assessing the balance of benefits and harms of screening for atrial fibrillation in asymptomatic adults
Findings may help with decision-making in this high-risk patient population.
Disparities seen among VA patients both for initiating any anticoagulant therapy and for initiating direct-acting oral anticoagulant use
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
Investigators found an incremental increase in risks from oral anticoagulants as kidney function decreased, highlighting the need for more research to better understand bleeding risk and net benefit of treatment in the CKD population.